Showing results (361-370 of 630) with videos related to

Sort By:
Pageof 63
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 17, 2020
Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis: A phase 2b randomized studyJonathan I Silverberg, Emma Guttman-Yassky, Melinda Gooderham, et al.
American Journal of Clinical Dermatology|October 20, 2022
Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III StudiesLisa Bloudek, Lawrence F Eichenfield, Jonathan I Silverberg, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 15, 2021
Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysisJ I Silverberg, J P Thyssen, K Fahrbach, et al.
Annals of Clinical and Laboratory Science|February 10, 2009
IgE anti-varicella zoster virus and other immune responses before, during, and after shinglesTamar A Smith-Norowitz, Joby Josekutty, Hadar Lev-Tov, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 12, 2018
Health Utility Scores of Atopic Dermatitis in US AdultsJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 18, 2019
Atopic Dermatitis in US Adults: From Population to Health Care UtilizationJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
International Journal of Biomedical Science : IJBS|May 16, 2013
Long Term Persistence of IgE Anti-Varicella Zoster Virus in Pediatric and Adult Serum Post Chicken Pox Infection and after Vaccination with Varicella Virus VaccineTamar A Smith-Norowitz, Joby Josekutty, Jonathan I Silverberg, et al.
Journal of the American Academy of Dermatology|February 10, 2024
Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a studyJonathan I Silverberg, Robert S Kirsner, David J Margolis, et al.
Pageof 63